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Introduction: With the development of therapeutics and vaccine against Ebola virus disease (EVD), the 
question of post-exposure prophylaxis for high-risk contact has emerged. Immunotherapies (monoclonal 
antibodies [mAbs]) recently validated for treating infected patients appear to be a good candidate for 
protecting contacts. 
Design: During the tenth EVD outbreak in the Democratic Republic of the Congo, we have administrated 
mAbs (Mab114 or REGN-EB3) to high and intermediate-risk contacts of EVD patients. 
Results: : Overall, 23 non-vaccinated contacts received mAbs after a median delay between contact and 
post-exposure prophylaxis of 1 day (interquartile range 1–2). All contacts were free of symptoms, and all 
had negative reverse transcriptase-polymerase chain reaction 14 days after the contact. 
Conclusion: Immunotherapies appear to be promising candidates to protect EVD contacts. Interaction 
with vaccine needs to be analyzed and a larger study on efficacy conducted. 
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 
This is an open access article under the CC BY-NC-ND license 

























Over the past decade, there have been significant advances in 
he management of Ebola virus disease (EVD), including the de- 
elopment of a vaccine (VSV-ZEBOV-GP, ERVEBO, Merck, USA) in- 
icated for ring vaccination of contacts ( Henao-Restrepo et al., 
017 ), and two immunotherapies (MAb114 and REGN-EB3) effec- 
ive against mortality in patients infected with Ebola virus (EBOV) 
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icense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) ssues have also emerged, including protection of high-risk con- 
acts, defined as post-exposure prophylaxis (PEP). 
Vaccination with ERVEBO is beneficial for breaking the trans- 
ission chains for EVD but has no place in PEP because antibody 
roduction occurs after 10 days ( Fischer et al., 2018 ; Iversen et al.,
020 ). Monoclonal antibodies (mAbs) represent a good therapeutic 
ption to be evaluated in PEP, as they effectively reduce mortality 
hen administered early in the course of the disease and are easy 
o administer as they require only one intravenous injection. 
esign 
During the tenth EVD outbreak in the Democratic Republic of 
he Congo, national response teams and caregivers of the non- 
overnmental organization The Alliance for International Medical 
ction administered MAb114 or REGN-E3B on an emergency-use 
asis for high-risk contact (direct contact with skin barrier breach 
ith a confirmed EVD patient) and intermediate-risk contact (di- ty for Infectious Diseases. This is an open access article under the CC BY-NC-ND 



















































































ect contact without skin barrier breach with an EVD patient), ac- 
ording to the WHO classification. 
esults 
Between 1 July 2019 and 31 January 2020, teams at the Ebola 
reatment centers in Beni, Katwa and Mambassa administered 
Ab114 (N = 21) or REGN-E3B (N = 2) to 23 individuals. These 
ndividuals had never received any Ebola vaccine. The median age 
f the participants was 30 years (interquartile range (IQR) 20–43) 
nd 14 (61%) were female. Among them, 8 (35%) were children 
 10 years old, 2 of whom were treated at birth (in utero exposure 
rom EBOV-infected mothers). Only 4 participants were health care 
orkers. The contact was high-risk for 18 (78%) individuals and 
ntermediate-risk for 5 (see table). The median time from contact 
o the administration of mAb was 1 day (IQR 1–2). The participants 
ere monitored until day 14 by reverse transcriptase-polymerase 
hain reaction (RT-PCR) and on-demand clinical follow-up. No par- 
icipants developed symptoms of EVD and all RT-PCR tests were 
egative. 
iscussion 
The secondary attack rate of EVD in the literature ranges 
rom 37% for direct contact to 80% for handling dead bodies 
 Bower et al., 2016 ). The use of mAbs in PEP has been shown to be
ffective in mice and non-human primates ( Brannan et al., 2019 ; 
roude et al., 2018 ). In addition, 4 health care workers have previ- 
usly been treated with a combination of mAbs and the antiviral 
avipiravir after intermediate or high-risk exposure; none of them 
eveloped EVD ( Jacobs et al., 2015 ). 
However, certain points need to be discussed. First, the World 
ealth Organization’s definition of contact cases does not mention 
he source patient’s clinical status. It seems likely that contact with 
 patient with ’wet’ Ebola (secretions, vomiting/diarrhea or exter- 
al bleeding) is more likely to result in contamination than con- 
act with a ’dry’ Ebola case. In addition, the notion of skin barrier 
reach, which classifies contact as high-risk, is not always easy to 
dentify in the field, particularly when it occurs despite personal 
rotective equipment. Therefore, we propose that PEP be offered to 
ndividuals who have had direct contact (with or without skin bar- 
ier breach) with a confirmed case of ’wet’ Ebola. Second, mAbs do 
ot provide sustained immunity and vaccination is subsequently 
andatory. However, ERVEBO and mAbs share the same viral tar- 
et, the envelope glycoprotein (GP) ( Cagigi et al., 2018 ). Therefore, 
t is likely that the vaccine will be inhibited by mAbs, especially 
hen administered concomitantly ( Fischer et al., 2018 ). Third, the 
verall protection strategy (PEP and vaccination) needs to be as- 
essed in terms of feasibility. If the PEP alternative is more effec- 
ive when administered soon after contact, as in our study, any 
trategy that leads to a delay, e.g., a few days after vaccination as 
roposed by Cross et al. ( Cross et al., 2020 ), might decrease the
fficacy and therefore render it an unsatisfactory operational op- 
ion. On the other hand, both the minimum time between mAb 
nd vaccine and the maximum time between contact and PEP ad- 
inistration remain to be defined. 
onclusion 
In conclusion, the use of mAbs in PEP represents an attractive 
ption in the protection of those who have had contact with an 
VD patient; however, phase 2 and phase 3 studies to validate the 
ffectiveness of this strategy are required, and the issues of feasi- 
ility and mAb-vaccine interaction need to be addressed. 167 uthor contribution statement 
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